News

Xtant Medical Introduces Innovative CollagenX for Wound Care

Xtant Medical Introduces Innovative CollagenX for Wound Care

Xtant Medical Unveils CollagenX™ for Enhanced Wound Closure

This launch enhances Xtant's portfolio in surgical wound care.

Xtant Medical Holdings, Inc. (NYSE American: XTNT), a prominent global medical technology enterprise specializing in surgical solutions, proudly announces the introduction of CollagenX™, a revolutionary bovine collagen particulate product designed specifically for surgical wound closure. This innovative product not only aims to promote healing but also addresses the frequent concerns associated with surgical site infections and dehiscence.

With the addition of CollagenX™, Xtant expands its biologics product offerings, catering to a variety of surgical procedures. This development underscores the company's commitment to enhancing patient care through advanced medical solutions.

CollagenX™: A Game Changer in Surgical Wound Care

Sean Browne, the President and CEO of Xtant Medical, expressed excitement about this launch: "With the introduction of CollagenX for surgical wound closure, we are not just enhancing our orthobiologics portfolio, but demonstrating our unwavering dedication to innovation and the diverse needs of both surgeons and patients. Our vertically integrated regenerative medicine foundation positions us uniquely in the market to deliver unparalleled quality and consistency, significantly improving patient outcomes."

CollagenX™ is strategically designed to be a valuable addition across every case addressed by Xtant's biologics portfolio. This versatility allows it to cater to various surgical disciplines, thus diversifying its application within the medical field.

Commitment to Innovation and Quality

Xtant Medical's mission revolves around honoring the gift of donation to enhance the lives of patients, ensuring they can live as fully as possible. With a focus on the design, development, and commercialization of a comprehensive array of orthobiologics, Xtant serves not just the chronic and surgical wound care markets but also sports medicine alongside spinal implant systems.

The team's dedication and expertise, driven by high ethical standards, allow Xtant Medical to offer unmatched service to its customer base. This commitment plays a crucial role in the introduction of innovative products like CollagenX™, reinforcing patient safety and recovery across various surgical applications.

Anticipating Future Developments

Looking ahead, Xtant Medical is committed to continuous innovation. The market is evolving, and as surgical procedures become more advanced, the need for effective wound care solutions like CollagenX™ becomes increasingly vital. Xtant's focus on patient outcomes drives its research and development teams to explore new avenues and technologies that further enhance the healing process.

As the healthcare landscape shifts, the importance of having reliable, effective products at the surgeon's disposal cannot be understated. Xtant Medical is well-positioned to adapt and thrive in this dynamic environment, ensuring its offerings meet the demands of modern surgical practices.

About Xtant Medical Holdings, Inc.

Xtant Medical Holdings, Inc. is recognized as a leader in the medical technology domains, emphasizing the importance of donation within its operational ethos. The organization focuses on producing state-of-the-art solutions in orthobiologics that support chronic and surgical wound care, as well as spinal implants.

By fostering a culture of innovation and dedication, Xtant consistently brings forward products that prioritize patient outcomes and healthcare standards. Their mission is complemented by a professional team devoted to upholding integrity and excellence in every aspect of service.

Frequently Asked Questions

What is CollagenX™?

CollagenX™ is a bovine collagen particulate product designed for surgical wound closure, intended to promote healing and mitigate infection risks.

How does CollagenX™ enhance patient care?

By promoting healing and addressing dehiscence and surgical site infections, CollagenX™ improves overall patient recovery and outcomes during surgical procedures.

What is Xtant Medical's mission?

Xtant Medical aims to honor the gift of donation, enhancing patient lives by providing effective medical solutions across various disciplines.

How does Xtant ensure quality in its products?

Xtant Medical benefits from being a fully vertically integrated regenerative medicine company, which enhances its ability to deliver consistent quality and innovative solutions.

Which markets does Xtant serve?

Xtant Medical focuses on orthobiologics for chronic and surgical wound care, sports medicine, and spinal implant systems, continuously expanding with products like CollagenX™.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Hugel's Sales Climb Despite Changes in Sales Models

Updated Category News Views 97

Hugel's Financial Fortunes in a Shifting Landscape Who would've thought? That’s the vibe hugging the numbers Hugel Inc. just dropped. Their performance for the first three quarters of 2026 is in the books, and results show consolidated net sales climbing 15% year-on-year. Just how did they pull this rabbit out of the hat? Let's dissect this a bit. Cracking the Code of...

Continue Reading
Are BWIN, LFCR, PCRX Shareholder Deals Fair?

Updated Category News Views 100

What's Really Going On with BWIN, LFCR, and PCRX? Everyone talks about when there's smoke, there's fire. But in this case, it’s hard not to wonder if we're standing knee-deep in burning embers, or just a dusty old campfire. Halper Sadeh LLC is ringing the alarm bells for Baldwin Group, Lifecore Biomedical, and Pacira BioSciences, the trio tagged under NASDAQ: BWIN,...

Continue Reading
MRP Securities Fraud: Investors Eye Millrose Case

Updated Category News Views 104

Millrose's Troubles: A Closer Look at the Fraud Accusation Now, here's a pickle. Millrose Properties, Inc. (NYSE: MRP) has landed itself in hot water. We've got a bona fide class action lawsuit on our hands, and Schall, Brown & Schwartz LLP is waving the flag, rallying investors to step up and face the music. Turns out the company's talk might not have walked the walk...

Continue Reading
Peabody's Q3 2026: Margins Climb Despite Net Loss

Updated Category News Views 0

Tough Quarters but Promising Margins Alright, Peabody's Q3 2026 isn't the most sunshine-filled report I've laid eyes on, but it's not all shadows either. Sure, they posted a net loss of $32.8 million, better than last year's $70.1 million drain. Admit it or not, that's improvement. And yet, the real gem here is those expanding margins gleaming despite the loss-heavy...

Continue Reading
Omnissa Expands AI Sovereignty: New Markets, New Control

Updated Category News Views 41

Omnissa Rolls Out AI Sovereignty Across New Markets In the world of AI, where data is king and control is the crown, Omnissa is making bold moves with its latest expansion announcement. The company's Sovereign Solution (OSS) is now reaching into six fresh markets across Europe and Asia, offering organizations a vital grip on their digital domains like never before. Talk...

Continue Reading
UN Forum Unleashes LatAm CEO Coalition for Action

Updated Category News Views 89

Latin America Takes Center Stage When the UN turns its spotlight on a region, you know there's something afoot. Right in Montevideo, Uruguay, the United Nations Global Compact gathered a hefty crowd of over 300 leaders from diverse backgrounds—think business, finance, government, and academia. What they were brewing wasn’t just talk; it was about driving real change...

Continue Reading
Lincoln Index Highlights Growth, But Risks Linger

Updated Category News Views 130

Private Market Dynamics: A Mixed Bag in Q3 The Lincoln Private Market Index (LPMI) is giving us quite the mixed message this quarter. Up by 2.8%, the index is applauding earnings growth in private companies. Not too shabby, right? Yet, let's not pop the champagne just yet. It's not all sunshine and roses—credit risk clouds are looming large. Steady Performers, but Not...

Continue Reading
Lumentum Holders Question Marvell Deal Fairness: Legal Eyes

Updated Category News Views 82

What's Brewing with Lumentum and Marvell? There's no denying the chatter on Wall Street when there's a potential shake-up, especially with a big merger at stake. We're staring down the barrel of an investigation concerning Lumentum Holdings Inc. (NASDAQ: LITE) and Marvell Technology, Inc.'s deal. The M&A Class Action Firm, helmed by Juan Monteverde, is the name leading...

Continue Reading
Fluence Energy Faces Legal Trouble: A Closer Look

Updated Category News Views 31

Fluence Energy's Legal Tangle: What It Means for Investors You ever get that gut punch feeling when a company you’re watching stumbles? Well, Fluence Energy, Inc. (NASDAQ: FLNC) seems to have handed that to its shareholders lately. There's a class action lawsuit out there that’s got investors not only scratching their heads but also reaching for their phones. The...

Continue Reading
EXPO 2027 Belgrade: Serbia's Tourism Game-Changer?

Updated Category News Views 104

An Unexpected Stage: Belgrade's Big Show Well, who's betting on Belgrade making waves in the global travel scene? EXPO 2027 is shaping up to do just that, and it’s taking the scenic route. Serbia, a country not always on the grand tourist itineraries, could finally hog the spotlight come 2027. Under the banner of 'Play for Humanity: Sport and Music for All,' they're...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Latest Trends in Alcohol Policy and Health Advances

Updated Category News Views 436

Exploring the Latest Trends in Alcohol Policy and Health Advances Alcohol Justice has unveiled its February 2025 eNews, delivering a thorough overview of significant news, research, and advocacy surrounding the effects of alcohol on communities and public health. This month’s publication emphasizes vital advancements in the sphere of alcohol policy, paying close...

Continue Reading
Explore the Exciting New Manor Collection at Sereno Canyon

Updated Category News Views 273

Announcing the Grand Opening of the Manor Collection Exciting news is on the horizon as Toll Brothers, Inc. (NYSE:TOL), the nation’s leading luxury home builder, proudly presents the grand opening of its new Manor Collection at Sereno Canyon. This exceptional community is nestled in the breathtaking landscape of Scottsdale and offers residents a blend of luxury,...

Continue Reading
Federal Home Loan Bank of Boston Reports Strong Financial Results

Updated Category News Views 170

Federal Home Loan Bank of Boston Reports 2024 Results The Federal Home Loan Bank of Boston declared its preliminary financial results for the fourth quarter and the year 2024. The Bank reported a significant net income of $82.1 million for the last quarter of 2024, contributing to an impressive annual total of $290.5 million. These results are expected to be highlighted...

Continue Reading
Understanding the Rising Short Interest in IBM Stock

Updated Category News Views 133

Understanding the Rising Short Interest in IBM Stock IBM's short interest has significantly increased, recently rising by 12.5%. Currently, there are 23.16 million shares that have been sold short, representing 2.52% of the total shares available for trading. With this level of short interest, it would take traders approximately 5.94 days to cover their short positions...

Continue Reading
AlphaTON and ADDRI Join Forces for Mesothelioma Clinical Research

Updated Category News Views 144

Exciting New Clinical Trial Initiative for Mesothelioma AlphaTON Capital Corp (NASDAQ: ATON) has made a significant stride in the fight against mesothelioma by partnering with Australia's Asbestos and Dust Diseases Research Institute (ADDRI). Together, they are setting the stage for an investigator-initiated clinical trial to evaluate TT-4, a promising selective A2B...

Continue Reading